Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with open angle glaucoma or ocular hypertension in both eyes~Exclusion Criteria:~* Patients at risk of progression of visual field loss~* Patients with severe visual field defect~* Patients with any diseases that preclude participation in this study for safety reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DE-117 ophthalmic solution (Type: EXPERIMENTAL): None
- Latanoprost ophthalmic solution 0.005% (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).